Royalty Pharma (RPRX) Equity Ratio (2019 - 2026)

Royalty Pharma has disclosed Equity Ratio across 8 years of filings, most recently posting 0.5 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.5, down 9.69% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.5 (down 9.69% YoY), and the FY2025 annual result was 0.5, down 12.76% from the prior year.
• Equity Ratio came in at 0.5 for Q1 2026 at Royalty Pharma, up from 0.5 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.62 in Q4 2023 to a low of 0.5 in Q4 2025.
• The 5-year median for Equity Ratio is 0.57 (2024), against an average of 0.56.
• Across the five-year window, Equity Ratio rose 8.66% in 2023 and declined 12.76% in 2025, its largest moves.
• Royalty Pharma's Equity Ratio stood at 0.57 in 2022, then advanced by 8.66% to 0.62 in 2023, then slipped by 7.8% to 0.57 in 2024, then fell by 12.76% to 0.5 in 2025, then climbed by 1.28% to 0.5 in 2026.
• The last three Equity Ratio figures came in at 0.5 (Q1 2026), 0.5 (Q4 2025), and 0.5 (Q3 2025), per Business Quant data.